| Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology A Stepanian, M Cohen-Moatti, T Sanglier, P Legendre, N Ameziane, ... Arteriosclerosis, thrombosis, and vascular biology 31 (7), 1703-1709, 2011 | 111 | 2011 |
| Comparing antidepressant treatment patterns in older and younger adults: a claims database analysis T Sanglier, D Saragoussi, D Milea, JP Auray, RJ Valuck, M Tournier Journal of the American Geriatrics Society 59 (7), 1197-1205, 2011 | 39 | 2011 |
| Depressed older adults may be less cared for than depressed younger ones T Sanglier, D Saragoussi, D Milea, M Tournier Psychiatry Research 229 (3), 905-912, 2015 | 28 | 2015 |
| Antidepressant treatment patterns in younger and older adults from the general population in a reallife setting F Etchepare, T Sanglier, M André, H Verdoux, M Tournier International journal of geriatric psychiatry 29 (9), 928-935, 2014 | 21 | 2014 |
| Drinking patterns and their predictive factors in CONTROL: A 12-month prospective study in a sample of alcohol-dependent patients initiating treatment JB Daeppen, M Faouzi, T Sanglier, N Sanchez, F Coste, N Bertholet Alcohol and alcoholism 48 (2), 189-195, 2013 | 15 | 2013 |
| Is it acceptable to destroy or include human embryos before day 5 in research programmes? M Poulain, L Hesters, T Sanglier, A de Bantel, R Fanchin, N Frydman, ... Reproductive BioMedicine Online 28 (4), 522-529, 2014 | 14 | 2014 |
| Increasing escitalopram dose is associated with fewer discontinuations than switch or combination approaches in patients initially on escitalopram 10mg T Sanglier, D Milea, D Saragoussi, M Toumi European psychiatry 27 (4), 250-257, 2012 | 7 | 2012 |
| T-DM1 after pertuzumab plus trastuzumab: treatment sequence-induced selection bias in HER2-positive metastatic breast cancer T Sanglier, A Fabi, C Flores, EM Flahavan, C Pena-Murillo, AM Meyer, ... Cancers 14 (10), 2468, 2022 | 6 | 2022 |
| Use of trastuzumab emtansine (T-DM1; K) after pertuzumab+ trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): challenges in assessing effectiveness … T Sanglier, A Fabi, C Flores, E Flahavan, N Lindegger, F Montemurro Annals of Oncology 30, v129, 2019 | 6 | 2019 |
| Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (mBC) and CNS metastases (CNS mets). A Shewade, AFC Hsieh, A Mani, NJA Al-Sakaff, T Sanglier, MD Taylor, ... Journal of Clinical Oncology 36 (15_suppl), 1037-1037, 2018 | 6 | 2018 |
| Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study T Sanglier, J Shim, N Lamarre, C Peña-Murillo, V Antao, F Montemurro The Breast 69, 441-450, 2023 | 3 | 2023 |
| Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in Sweden A Valachis, M Sundqvist, L Carlsson, B Li, F Chiesa, M Uhde, T Sanglier Future Oncology 15 (23), 2733-2741, 2019 | 3 | 2019 |
| Quantifying the impact of mortality underreporting on analyses of overall survival MT Bretscher, T Sanglier 34th International Conference for Pharcoepidemiology and Risk Management …, 2018 | 3 | 2018 |
| Comparaison de la prise en charge de la dépression chez le sujet âgé et l’adulte non âgé par l’utilisation de systèmes administratifs automatisés. T Sanglier Université Claude Bernard-Lyon I, 2011 | 3 | 2011 |
| Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Comparative Effectiveness Study … L Polito, J Shim, SA Hurvitz, CT Dang, A Knott, Y Du Toit, E Restuccia, ... JCO Oncology Practice 19 (7), 435-445, 2023 | 2 | 2023 |
| Trastuzumab-based regimens beyond progression: a crucial treatment option for HER2+ advanced/metastatic breast cancer T Sanglier, R Ross, T Shi, J Mouta, S Swain, F Cardoso The Breast 66, 262-271, 2022 | 2 | 2022 |
| Metastatic breast cancer sub-type classification using biomarker and treatment information in electronic health records C Craggs, EM Flahavan, A Surinach, M Kent, T Sanglier PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 28, 73-73, 2019 | 2 | 2019 |
| 252P Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world … C Labaki, Z Bakouny, T Sanglier, A Schmidt, J Shim, DA Braun, F Bouquet, ... Annals of Oncology 33, S652, 2022 | 1 | 2022 |
| Clinical characteristics and real-world progression-free survival (rwPFS) of patients with HER2-positive and hormone receptor (HR)-positive metastatic breast cancer (MBC … T Sanglier, J Shim, D Eiger, R Poppe, E Restuccia Journal of Clinical Oncology 40 (16_suppl), e13028-e13028, 2022 | 1 | 2022 |
| Abstract PS10-20: Neoadjuvant (neoadj) and adjuvant (adj) treatment patterns in HER2-positive early breast cancer (EBC): Analysis of US real-world oncology data PK Dhillon, C Flores, T Sanglier, V Antao, D Tesarowski, A Fung, D Incerti, ... Cancer Research 81 (4_Supplement), PS10-20-PS10-20, 2021 | 1 | 2021 |
